ObsEva (OBSV) Stock Price, News & Analysis

Company Overview

ObsEva SA was a Swiss biopharmaceutical company focused on developing and commercializing therapies for women’s reproductive health. Founded in 2012 and headquartered in Geneva, the company concentrated on conditions including uterine fibroids, endometriosis and infertility-related complications.

ObsEva’s principal product candidate was linzagolix, an oral gonadotropin-releasing hormone antagonist designed to reduce hormone production associated with uterine fibroids and endometriosis. The therapy was approved in the European Union under the brand name Yselty for the treatment of moderate to severe symptoms of uterine fibroids. ObsEva also developed other reproductive-health candidates, including treatments intended for endometriosis and assisted reproductive technology.

The company conducted research and clinical-development activities in Europe and the United States and listed its shares on the Nasdaq Global Select Market in 2017. Ernest Loumaye, a co-founder of ObsEva, served as its chief executive officer during much of its operating history. ObsEva later entered financial difficulties and pursued restructuring measures, and its publicly traded operations were subsequently wound down; its historical business and product assets have been subject to transactions involving other pharmaceutical companies.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 1,763 shs
• Average Volume: 8.94 million shs
• Market Capitalization: $7.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/04/2021
• Today: 9/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:OBSV
• CIK: 1685316
• Web: www.obseva.com
• Phone: (122) 552-3840
• Fax: N/A
• Employees: 50
• Year Founded: 2012

Profitability

• EPS (Trailing Twelve Months): ($0.92)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$58.38 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -416.36%
• Return on Assets: -92.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.61
• Quick Ratio: 0.61

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.41 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 77,971,000
• Free Float: 66,743,000
• Market Cap: $7.94 million
• Optionable: Not Optionable
• Beta: 0.68